Ventricular Lead Dislodgement Detection via EGM Amplitude Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current implantable medical devices face challenges in reliably detecting ventricular lead dislodgement, which can lead to inappropriate sensing of cardiac rhythms and therapy delivery, due to changes in cardiac electrogram signals.
Innovation Solution
The system detects ventricular lead dislodgement by analyzing changes in near-field and far-field cardiac electrogram signals, specifically looking for variability in R-wave amplitudes, increased P-wave amplitudes, and patterns like short-long-short-long (SLSL) in RR intervals, to provide an alert and adjust therapy delivery accordingly.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the implantable medical device uses standard sensing methods to detect cardiac rhythms, then the device can provide basic pacing and defibrillation therapy, but the device cannot reliably detect ventricular lead dislodgement, leading to inappropriate therapy delivery
Solution Approach 1:
The patent segments the cardiac EGM signal analysis into multiple independent parameters: R-wave amplitude, P-wave amplitude, RR interval variability, and signal morphology. Each parameter is evaluated separately to detect lead dislodgement, allowing the system to achieve reliable detection without requiring a single complex sensing mechanism
Solution Approach 2:
The implantable medical device uses its existing sensing circuitry and processing capabilities to perform multiple functions: standard cardiac rhythm sensing, lead dislodgement detection through multiple parameters, and therapy delivery. The same hardware infrastructure supports both routine monitoring and dislodgement detection, avoiding the need for dedicated additional components
2Measurement precision
If the device monitors multiple EGM parameters to detect lead dislodgement, then the detection accuracy improves, but the processing complexity and computational load increase
Solution Approach 1:
The patent evaluates multiple EGM parameters (R-wave amplitude, P-wave amplitude, RR interval variability, signal morphology) to detect lead dislodgement. By monitoring more parameters than the minimum single parameter needed, the system achieves higher detection precision and reduces false positives, with the added computational burden acceptable given the life-critical nature of accurate detection
3Object-affected harmful factors
If the device withholds therapy when lead dislodgement is suspected, then inappropriate shock delivery is prevented, but necessary therapy may be delayed or denied
Solution Approach 1:
The patent implements preliminary anti-action by withholding anti-tachycardia therapy when lead dislodgement is detected, preventing the harmful effect of inappropriate shock delivery. The system proactively blocks potential harmful therapy before it can be delivered, then seeks confirmation through additional parameter analysis or physician intervention to determine if therapy should ultimately be administered
Solution Approach 2:
The system uses feedback mechanisms to continuously monitor EGM parameters and adjust therapy delivery decisions. When lead dislodgement is suspected, the system withholds therapy and seeks additional confirmation through further parameter analysis or physician input, then delivers therapy only when confidence in the diagnosis is sufficient, ensuring both safety and appropriateness of treatment
Data Source
AI summary
Detecting dislodgement of a ventricular lead coupled to an implantable medical device comprises sensing a near-field cardiac EGM via a first electrode of the ventricular lead and a far-field cardiac EGM via a second electrode of the ventricular lead, identifying, R-waves in the near-field cardiac EGM and the far-field cardiac EGM. determining a near-field value of one or more R-wave amplitude metrics based on amplitudes of R-waves identified in the near-field cardiac EGM and a far-field value of the one or more R-wave amplitude metrics based on amplitudes of R-waves identified in the far-field cardiac EGM, detecting dislodgement of the ventricular lead based on at least one of the near-field value or the far-field value of the one or more R-wave amplitude metrics; and providing a lead dislodgment alert in response to detecting the dislodgement of the ventricular lead.